Our CML assay panel comprises 13 different iDDS probes for the most common secondary mutations in ABL kinase that confer drug resistance in patients with CML.
GeneTAG has developed iDDS probe assays against a panel of key driver mutations associated with colorectal cancer.
We offer iDDS probes against common driver mutations in IDH1 (R132C, R132H) and IDH2 (R172K, R172M), which have been implicated in gliomas.
We offer iDDS probe assays against common EGFR driver mutations (L858R and exon 19 deletions), the T790M drug-resistance mutation, and 16 other resistance mutations.
GeneTAG Technology, Inc.
Copyright © 2023 GeneTAG Technology - All Rights Reserved.
Powered by GoDaddy